A bisphenol that is 4,4'-methanediyldiphenol in which the methylene hydrogens are replaced by two methyl groups.
Chemical ID:
MESH:C006780
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction
is comprised of a complex set of reactions and/or regulatory events, possibly involving
additional chemicals and/or gene products.
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; [bisphenol A co-treated with Estradiol] results in increased expression of MAPK3 mRNA; [bisphenol A co-treated with Glutamic Acid] results in increased phosphorylation of MAPK3 protein; afimoxifene inhibits the reaction [[bisphenol A co-treated with Glutamic Acid] results in increased phosphorylation of MAPK3 protein]; bisphenol A affects the reaction [Estradiol affects the phosphorylation of MAPK3 protein]; bisphenol A affects the reaction [Estriol affects the phosphorylation of MAPK3 protein]; bisphenol A affects the reaction [Estrone affects the phosphorylation of MAPK3 protein]; bisphenol A inhibits the reaction [[Dihydrotestosterone co-treated with Glutamic Acid] results in increased phosphorylation of MAPK3 protein]; bisphenol A inhibits the reaction [[Estradiol co-treated with Glutamic Acid] results in increased phosphorylation of MAPK3 protein]; bisphenol A inhibits the reaction [Estradiol results in increased phosphorylation of MAPK3 protein]; bisphenol A inhibits the reaction [NGF protein results in increased phosphorylation of MAPK3 protein]; bisphenol A results in decreased expression of and results in decreased phosphorylation of MAPK3 protein; crocin inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Flutamide inhibits the reaction [[bisphenol A co-treated with Glutamic Acid] results in increased phosphorylation of MAPK3 protein]; Fulvestrant inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; NF023 inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Nystatin inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Phytochemicals inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]
1,3-bis(4-hydroxyphenyl)-4-methyl-5-(4-(2-piperidinylethoxy)phenol)-1H-pyrazole inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; 4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [[bisphenol A co-treated with LEP protein] results in decreased activity of CASP3 protein]; [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [[LEP protein co-treated with bisphenol A] results in decreased expression of CASP3 protein]; [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [bisphenol A results in decreased activity of CASP3 protein]; [2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one results in decreased activity of [MAPK1 protein co-treated with MAPK3 protein]] inhibits the reaction [bisphenol A results in decreased expression of CASP3 protein]; [bisphenol A co-treated with Dibutyl Phthalate] results in decreased phosphorylation of MAPK3 protein; [bisphenol A co-treated with Diethylhexyl Phthalate] results in decreased phosphorylation of MAPK3 protein; [bisphenol A co-treated with LIF protein] results in increased phosphorylation of MAPK3 protein; [bisphenol A co-treated with mono-(2-ethylhexyl)phthalate] results in increased phosphorylation of MAPK3 protein; [GPER1 protein co-treated with bisphenol A] results in increased phosphorylation of MAPK3 protein; [GPER1 protein results in increased susceptibility to bisphenol A] which results in increased phosphorylation of MAPK3 protein; [mono-(2-ethylhexyl)phthalate co-treated with bisphenol A] inhibits the reaction [HDAC6 protein affects the phosphorylation of MAPK3 protein]; [Tetradecanoylphorbol Acetate co-treated with bisphenol A] results in increased phosphorylation of MAPK3 protein; Acetylcysteine inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; astaxanthine inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; bicalutamide inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; bisphenol A inhibits the reaction [HDAC6 protein affects the phosphorylation of MAPK3 protein]; bisphenol A inhibits the reaction [INS1 protein results in increased phosphorylation of MAPK3 protein]; bisphenol A promotes the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]; bisphenol A results in increased phosphorylation of and results in increased activity of MAPK3 protein; ESR1 protein affects the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Fulvestrant inhibits the reaction [[bisphenol A co-treated with Dibutyl Phthalate] results in decreased phosphorylation of MAPK3 protein]; Fulvestrant inhibits the reaction [[bisphenol A co-treated with Diethylhexyl Phthalate] results in decreased phosphorylation of MAPK3 protein]; Fulvestrant inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with bisphenol A] results in increased phosphorylation of MAPK3 protein]; Fulvestrant inhibits the reaction [bisphenol A results in decreased phosphorylation of MAPK3 protein]; Fulvestrant inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; GPER1 mRNA affects the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Melatonin inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Phytochemicals inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; pyrazolanthrone inhibits the reaction [bisphenol A inhibits the reaction [INS1 protein results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; [bisphenol A co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased expression of MAPK3 mRNA; [bisphenol A co-treated with 1-Methyl-3-isobutylxanthine co-treated with Dexamethasone co-treated with INS protein] results in increased phosphorylation of MAPK3 protein; [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diethyl phthalate co-treated with di-n-octyl phthalate co-treated with diisodecyl phthalate co-treated with diisononyl phthalate] results in increased expression of MAPK3 protein; [bisphenol A co-treated with Diethylhexyl Phthalate co-treated with diethyl phthalate co-treated with diisononyl phthalate co-treated with di-n-octyl phthalate co-treated with Dibutyl Phthalate co-treated with butylbenzyl phthalate co-treated with diisodecyl phthalate] results in increased phosphorylation of MAPK3 protein; [bisphenol A results in increased phosphorylation of and results in increased activity of MAPK3 protein] which results in increased expression of NR4A1 mRNA; bisphenol A inhibits the reaction [Estradiol results in increased phosphorylation of MAPK3 protein]; bisphenol A inhibits the reaction [Estriol results in increased phosphorylation of MAPK3 protein]; bisphenol A inhibits the reaction [Estrone results in increased phosphorylation of MAPK3 protein]; bisphenol A inhibits the reaction [TNFSF11 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; bisphenol A results in increased expression of and affects the phosphorylation of MAPK3 protein; bisphenol A results in increased phosphorylation of and results in increased activity of MAPK3 protein; FOS protein affects the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Fulvestrant inhibits the reaction [bisphenol A results in increased activity of MAPK3 protein]; Fulvestrant inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Fulvestrant promotes the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Ginsenosides inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; GPER1 protein affects the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; W 7 inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]
